Articles by Yeh-Chia Tseng in JoVE
Human Pluripotent Stem Cell Culture on Polyvinyl Alcohol-Co-Itaconic Acid Hydrogels with Varying Stiffness Under Xeno-Free Conditions Tzu-Cheng Sung*1, Hsing-Fen Li*1, Akon Higuchi1,2, Qing-Dong Ling3,4, Jia-Sin Yang1, Yeh-Chia Tseng1, Chih-Hsien Pan Pan1, Abdullah A. Alarfaj2, Murugan A. Munusamy2, Suresh Kumar5, Shih-Tien Hsu6, Kadarkarai Murugan7,8 1Department of Chemical and Materials Engineering, National Central University, 2Department of Botany and Microbiology, King Saud University, 3Cathay Medical Research Institute, Cathay General Hospital, 4Graduate Institute of Systems Biology and Bioinformatics, National Central University, 5Department of Medical Microbiology and Parasitology, Universiti Putra Malaysia, 6Department of Internal Medicine, Taiwan Landseed Hospital, 7Department of Zoology, Bharathiar University, 8Thiruvalluvar University A protocol is presented to prepare polyvinyl alcohol-co-itaconic acid hydrogels with varying stiffness, which were grafted with and without oligopeptides, to investigate the effect of the stiffness of biomaterials on the differentiation and proliferation of stem cells. The stiffness of the hydrogels was controlled by the crosslinking time.
Other articles by Yeh-Chia Tseng on PubMed
Stem Cell Therapies for Myocardial Infarction in Clinical Trials: Bioengineering and Biomaterial Aspects Laboratory Investigation; a Journal of Technical Methods and Pathology. | Pubmed ID: 28869589 Cardiovascular disease remains the leading cause of death and disability in advanced countries. Stem cell transplantation has emerged as a promising therapeutic strategy for acute and chronic ischemic cardiomyopathy. The current status of stem cell therapies for patients with myocardial infarction is discussed from a bioengineering and biomaterial perspective in this review. We describe (a) the current status of clinical trials of human pluripotent stem cells (hPSCs) compared with clinical trials of human adult or fetal stem cells, (b) the gap between fundamental research and application of human stem cells, (c) the use of biomaterials in clinical and pre-clinical studies of stem cells, and finally (d) trends in bioengineering to promote stem cell therapies for patients with myocardial infarction. We explain why the number of clinical trials using hPSCs is so limited compared with clinical trials using human adult and fetal stem cells such as bone marrow-derived stem cells.